Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy

被引：0
|
作者：
Ahn, Hee Kyung [1 ]
Kim, Young Saing [2 ]
Kim, Eun Young [3 ]
Kyung, Sun Young [4 ]
Kang, Shin Myung [4 ]
Cho, Eun Kyung [1 ]
机构：
[1] Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Hematol & Oncol, Incheon, South Korea
[2] Gachon Univ, Gil Med Ctr, Incheon, South Korea
[3] Gachon Univ, Gil Med Ctr, Dept Radiol, Incheon, South Korea
[4] Gachon Univ, Gil Med Ctr, Pulm Med, Incheon, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
non-small cell lung cancer; Platinum; refractory; chemotherapy;
D O I：
10.1016/j.jtho.2016.11.1246
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.03a-037
引用
收藏
页码：S910 / S911
页数：2
相关论文
共 50 条
  • [1] Associations between biomarkers and outcomes of first-line chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Gronberg, B. H.
    Lund-Iversen, M.
    Strom, E. H.
    Brustugun, O. T.
    Scott, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC)
    Butts, C. A.
    Bodkin, D.
    Middleman, E. L.
    Englund, C. W.
    Ellison, D.
    Alam, Y. Z.
    Pautret, V.
    Weber, M.
    Kreisman, H.
    Shepherd, F. A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Outcomes for platinum doublet chemotherapy before and after first-line immune checkpoint inhibition in advanced non-small cell lung cancer (NSCLC)
    Lewis, Jacob
    Woodhouse, Laura
    Adderley, Helen
    Carter, Matt
    Brown, Kate
    Morrissey, George
    Nicola, Pantelis
    Weaver, Jamie
    Califano, Raffaele
    Summers, Yvonne
    Cove-Smith, Laura
    Hughes, Sarah
    Taylor, Paul
    Blackhall, Fiona
    Lindsay, Colin
    [J]. LUNG CANCER, 2023, 178 : S34 - S34
  • [4] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    [J]. ONKOLOGIE, 2003, 26 : 26 - 32
  • [5] First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
    Andric, Z. G.
    Galffy, G.
    Cobo Dols, M.
    Szima, B.
    Stojanovic, G.
    Petrovic, M. D.
    Felip Font, E.
    Vicente Baz, D.
    Ponce Aix, S.
    Juan-Vidal, O.
    Tehenes, S.
    Szalai, Z.
    Losonczy, G.
    Calles Blanco, A.
    Bernabe, R.
    Duecker, K.
    Zhou, D.
    Schroeder, A.
    Guezel, G.
    Ciardiello, F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S753 - S754
  • [6] Pembrolizumab in Combination with Chemotherapy as First-Line Treatment of Advanced Non-Small Cell Lung Cancer
    Jahan, N.
    Swarup, S.
    Sultan, A.
    Naing, T.
    Mogollon-Duffo, F.
    Ball, S.
    Tun, A.
    Htut, T.
    Dash, A.
    D'Cunha, N.
    Hardwicke, F.
    Awasthi, S.
    Tijani, L.
    Thein, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S917 - S918
  • [7] Biweekly docetaxel and gemcitabine as first line chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Gaspar, E.
    Firvida, J.
    Amenedo, M.
    Orts, D.
    Salgado, M.
    LLorca, C.
    Ramos, M.
    Perez, E.
    Cervera, J.
    Abal, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Han, B.
    Chu, T.
    Zhang, X.
    Zhong, H.
    Zhang, B.
    Wang, H.
    Gu, A.
    Zhang, W.
    Shi, C.
    Zhong, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S398
  • [9] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [10] Chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    [J]. LUNG CANCER, 2002, 38 : S47 - S50
12345